MEB-1170 is under clinical development by Mebias Discovery and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MEB-1170’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEB-1170 is under development for the treatment of pain, nociceptive pain and opioid use disorder. It is administered through oral route. The drug candidate acts by targeting mu-opioid receptors. These are backup molecules.
Mebias Discovery overview
Mebias Discovery carries out the discovery pathway-selective G-protein coupled receptor (GPCR) drugs. The company develops GPCR drugs in the therapeutic areas of neuroscience or pain, gastroparesis, metabolic and inflammatory-related disorders. Its drug candidates include MEB-1166, and MEB-1170 which targets neurodegenerative disorders, cardiovascular, mood disorders, pain (non-opioid), and immune-oncology. The company develops GPCR drugs by utilizing its specialized technologies such as native GPCR purification and protein nuclear magnetic resonance, which helps to decrease time and cost for delivering preclinical candidates to IND pipelines. It partners with pharmaceutical firms on specific targets, and advances its own molecules into early clinical development. Mebias discovery is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of MEB-1170’s drug-specific PTSR and LoA scores, buy the report here.